Corteva, Inc. (CTVA) Balance Sheet

The equity has remained remarkably consistent, ranging from $23.8B to $25.9B, suggesting that retained earnings and share repurchases are roughly offsetting. The slight dip in equity in 2025Q4 to $24.1B, alongside a negative retained earnings balance, appears to be a seasonal artifact rather than a structural deterioration. This stability, combined with a fortress-like debt profile, implies that the balance sheet is not a constraint on strategic flexibility.

Total debt fluctuates seasonally, rising to $5.7B in 2024Q3 and falling to $2.6B in 2025Q4, likely tied to working capital needs during planting season. The low leverage, especially compared to peers like FMC (D/E 2.0), suggests that CTVA is not reliant on debt to fund operations. This positions the company to weather commodity price downturns without refinancing risk, and the recent biologicals acquisitions appear to be funded from internal cash reserves rather than incremental borrowing.

The stability of goodwill around $10.4-10.6B suggests no impairment charges, but the concentration in intangibles implies that the balance sheet is sensitive to the continued success of the seed trait pipeline. The relatively low PPE, which jumped to $9.7B in 2026Q2 from $4.2B in prior quarters, may indicate a reclassification or acquisition, but the overall capital intensity remains low. This asset mix supports high returns on invested capital, but investors should monitor any future goodwill write-downs if the biologicals acquisitions underperform.

The negative retained earnings in 2025Q4 is a seasonal low point, but the recovery to $1.2B by 2026Q2 shows the cyclicality of the business. The stable equity base suggests that share repurchases and dividends are being funded by earnings, not by eroding the balance sheet. The lack of stock-based compensation, as noted in prior analysis, implies that dilution is not a concern, and the equity quality appears high.

The current ratio dipped to 1.43 in 2025Q4, but that coincided with peak cash of $4.5B, indicating that the ratio is driven by seasonal working capital needs. The cash position is modest relative to total assets, but the low debt and strong cash generation during peak seasons suggest that liquidity is not a concern. However, the negative operating cash flow in Q1, as noted in the cash flow analysis, means that CTVA relies on its balance sheet to bridge the seasonal gap, which it does comfortably.

The pattern of deferred revenue building up in Q4 and Q1, then being recognized in Q2, is typical for the agricultural inputs industry. The high levels in 2025Q4 and 2026Q1 suggest that farmers were committing to purchases early, which bodes well for the upcoming season. However, the softening commodity prices may lead to lower order volumes in the next cycle, and investors should monitor whether deferred revenue continues to grow year-over-year.